Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status approved
ATC Code L02BX03
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 42291-024; 42291-073; 69238-1754; 60219-1754; 60687-455; 17337-0082; 54893-0070; 30007-838; 69238-1165; 60219-1165
UNII G819A456D0
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.001235%Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.003--Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.001001%
Dizziness postural02.11.04.008; 24.06.02.008; 17.02.05.0040.000734%Not Available
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.002169%Not Available
Drug ineffective08.06.01.0060.129634%Not Available
Duodenal ulcer07.04.02.0020.000667%
Duodenal ulcer haemorrhage24.07.02.020; 07.04.02.0040.000334%Not Available
Dyspepsia07.01.02.001--
Dysphagia07.01.06.0030.070906%
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.0020.007107%
Eating disorder19.09.01.008; 14.03.01.0080.003370%Not Available
Electrolyte imbalance14.05.01.0020.002236%Not Available
Emphysema22.01.02.0020.000334%Not Available
Eructation07.01.02.0030.001702%
Erythema multiforme23.03.01.003; 10.01.03.0150.001168%
Extrasystoles02.03.02.0030.000901%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.002536%
Fatigue08.01.01.0020.151189%
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.0020.006974%
Fluid retention20.01.02.003; 14.05.06.0020.012246%Not Available
Fracture15.08.02.001; 12.04.02.001--
Gait disturbance15.03.05.013; 17.02.05.016; 08.01.02.002--
Gallbladder disorder09.03.02.0010.001068%Not Available
Gastric ulcer07.04.03.0020.000834%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 12 Pages